Sandoz, Novartis must face US antitrust claims over generic drugs, states argue
MLex Summary: US state attorneys general opposed Novartis AG and Sandoz AG’s motions to dismiss antitrust claims over an alleged generic drug price-fixing conspiracy, saying they cannot claim to be strangers...To view the full article, register now.
Already a subscriber? Click here to view full article